{"id":"https://openalex.org/W4362494276","doi":"https://doi.org/10.1158/1535-7163.22500232","title":"Supplementary Table 1 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion","display_name":"Supplementary Table 1 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362494276","doi":"https://doi.org/10.1158/1535-7163.22500232"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22500232","doi":"https://doi.org/10.1158/1535-7163.22500232","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22500232","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Potential_Advantages_of_CUDC-101_a_Multitargeted_HDAC_EGFR_and_HER2_Inhibitor_in_Treating_Drug_Resistance_and_Preventing_Cancer_Cell_Migration_and_Invasion/22500232/1/files/39959509.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Potential_Advantages_of_CUDC-101_a_Multitargeted_HDAC_EGFR_and_HER2_Inhibitor_in_Treating_Drug_Resistance_and_Preventing_Cancer_Cell_Migration_and_Invasion/22500232/1/files/39959509.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100378537","display_name":"Jing Wang","orcid":"https://orcid.org/0000-0002-5398-0802","observed_orcids":["https://orcid.org/0000-0002-5398-0802","https://orcid.org/0000-0001-5412-9860"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091117919","display_name":"Natalie W. Pursell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Natalie W. Pursell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110461270","display_name":"Maria Samson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Elena S. Samson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065104224","display_name":"Ruzanna Atoyan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ruzanna Atoyan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Anna W. Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna W. Ma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039372671","display_name":"Abdelkader Selmi","orcid":"https://orcid.org/0000-0001-5760-0507","observed_orcids":["https://orcid.org/0000-0001-5760-0507"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abdelkader Selmi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071635528","display_name":"Wanlu Xu","orcid":"https://orcid.org/0000-0002-8838-9879","observed_orcids":["https://orcid.org/0000-0002-8838-9879"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wanlu Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100770695","display_name":"Xiong Cai","orcid":"https://orcid.org/0000-0003-2034-9130","observed_orcids":["https://orcid.org/0000-0003-2034-9130"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiong Cai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079238859","display_name":"Maurizio Voi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maurizio Voi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002455905","display_name":"Pierre Savagner","orcid":"https://orcid.org/0000-0002-8287-2229","observed_orcids":["https://orcid.org/0000-0002-8287-2229"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pierre Savagner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5018703558","display_name":"Cheng-Jung Lai","orcid":"https://orcid.org/0000-0002-3321-8984","observed_orcids":["https://orcid.org/0000-0002-3321-8984"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheng-Jung Lai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.7519999742507935,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.7519999742507935,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.12489999830722809,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.08420000225305557,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cudc-101","display_name":"CUDC-101","score":1.0},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8399999737739563},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9240000247955322},{"id":"https://openalex.org/keywords/her2-inhibitors","display_name":"HER2 inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7879999876022339},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.7850000262260437},{"id":"https://openalex.org/keywords/hcc827-cells","display_name":"HCC827 cells","score":0.9300000071525574},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.6930000185966492},{"id":"https://openalex.org/keywords/tumor-cell-migration","display_name":"tumor cell migration","score":0.8410000205039978},{"id":"https://openalex.org/keywords/tumor-invasion","display_name":"tumor invasion","score":0.8500000238418579},{"id":"https://openalex.org/keywords/ic50","display_name":"IC50","score":0.8399999737739563}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.842420220375061},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5899724364280701},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5492895841598511},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4429692029953003},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.4234985411167145},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37352854013442993},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34099677205085754},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3083679676055908},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30379313230514526},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2948352098464966},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.26312869787216187},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17271581292152405},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.09732329845428467}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22500232","doi":"https://doi.org/10.1158/1535-7163.22500232","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22500232","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Potential_Advantages_of_CUDC-101_a_Multitargeted_HDAC_EGFR_and_HER2_Inhibitor_in_Treating_Drug_Resistance_and_Preventing_Cancer_Cell_Migration_and_Invasion/22500232/1/files/39959509.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22500232.v1","doi":"https://doi.org/10.1158/1535-7163.22500232.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22500232.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22500232","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Potential_Advantages_of_CUDC-101_a_Multitargeted_HDAC_EGFR_and_HER2_Inhibitor_in_Treating_Drug_Resistance_and_Preventing_Cancer_Cell_Migration_and_Invasion/22500232","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22500232","doi":"https://doi.org/10.1158/1535-7163.22500232","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22500232","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Potential_Advantages_of_CUDC-101_a_Multitargeted_HDAC_EGFR_and_HER2_Inhibitor_in_Treating_Drug_Resistance_and_Preventing_Cancer_Cell_Migration_and_Invasion/22500232/1/files/39959509.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362494276.pdf","grobid_xml":"https://content.openalex.org/works/W4362494276.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362495338","https://openalex.org/W2164868034","https://openalex.org/W2058961982","https://openalex.org/W2068473772","https://openalex.org/W4392684655","https://openalex.org/W4361945450","https://openalex.org/W2314812170","https://openalex.org/W2118661220","https://openalex.org/W2135971557","https://openalex.org/W2322593713"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"28K,":[3],"Growth":[4],"inhibitory":[5],"IC50s":[6],"of":[7],"indicated":[8],"compounds":[9],"in":[10],"parental":[11],"and":[12],"erlotinib-TR":[13],"HCC827":[14],"cells.":[15]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}